Akinion Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fusion Antibodies, a Belfast-based pharmaceutical contract research company, has appointed Dr Richard Jones as its chief executive.
He replaces Dr Paul Kerr who is standing down from the board with immediate effect in order to pursue other opportunities.
Dr Kerr will become a consultant to the company.
Fusion Antibodies said Dr Jones has 25 years’ experience in the pharmaceutical industry both in big pharma and biotech companies as well as running a contract development and manufacturing organisation (CDMO).
He joins Fusion from BrYet, a biotech company focused on the discovery and development of transtherapeutics nanotechnology used for the treatment of metastatic liver and lung cancers. ....

United Kingdom , Northern Ireland , City Of , Simon Douglas , Paul Kerr , Richard Jones , Queen University Belfast , London Stock Exchange , Shire Pharmaceuticals , Akinion Pharmaceuticals , Fusion Antibodies , Akcea Therapeutics , Holostem Advanced Therapies , Global Oncology , Mammalian Antibody , Molecular Oncology , University Belfast , ஒன்றுபட்டது கிஂக்டம் , வடக்கு ஐயர்ல்யாஂட் , நகரம் ஆஃப் , சிமோன் டக்ளஸ் , பால் கெர் , ரிச்சர்ட் ஜோன்ஸ் , ராணி பல்கலைக்கழகம் பெல்ஃபாஸ்ட் , லண்டன் ஸ்டாக் பரிமாற்றம் , ஶைர் மருந்துகள் ,